WO2002069947A3 - Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer - Google Patents

Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer Download PDF

Info

Publication number
WO2002069947A3
WO2002069947A3 PCT/IB2002/002002 IB0202002W WO02069947A3 WO 2002069947 A3 WO2002069947 A3 WO 2002069947A3 IB 0202002 W IB0202002 W IB 0202002W WO 02069947 A3 WO02069947 A3 WO 02069947A3
Authority
WO
WIPO (PCT)
Prior art keywords
trichostatin
hdac
antisense oligonucleotides
histone deacetylase
analogue
Prior art date
Application number
PCT/IB2002/002002
Other languages
French (fr)
Other versions
WO2002069947A2 (en
Inventor
Jeffrey M Besterman
Claire Bonfils
Soon Hyung Woo
Arkadii Vaisburg
Daniel Delorme
Marielle Fournel
Rico Lavoie
Zuomei Li
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Priority to JP2002569124A priority Critical patent/JP2004520421A/en
Priority to GB0316313A priority patent/GB2389365A/en
Priority to CA002434601A priority patent/CA2434601A1/en
Priority to KR10-2003-7009362A priority patent/KR20040018328A/en
Priority to DE10295684T priority patent/DE10295684T9/en
Publication of WO2002069947A2 publication Critical patent/WO2002069947A2/en
Publication of WO2002069947A3 publication Critical patent/WO2002069947A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Abstract

This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-4 and HDAC-1 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level. Specific inhibitors are antisense oligonucleotides against HDAC-4 and HDAC-1 and trichostatin analoques .
PCT/IB2002/002002 2001-01-12 2002-01-14 Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer WO2002069947A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002569124A JP2004520421A (en) 2001-01-12 2002-01-14 Method for specifically inhibiting histone deacetylase-4
GB0316313A GB2389365A (en) 2001-01-12 2002-01-14 Methods for specifically inhibiting histone deacetylase-4
CA002434601A CA2434601A1 (en) 2001-01-12 2002-01-14 Methods for specifically inhibiting histone deacetylase-4
KR10-2003-7009362A KR20040018328A (en) 2001-01-12 2002-01-14 Methods for specifically inhibiting histone deacetylase-4
DE10295684T DE10295684T9 (en) 2001-01-12 2002-01-14 Method of specifically inhibiting histone deacetylase-4

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26152201P 2001-01-12 2001-01-12
US26167401P 2001-01-12 2001-01-12
US60/261,522 2001-01-12
US60/261,674 2001-01-12

Publications (2)

Publication Number Publication Date
WO2002069947A2 WO2002069947A2 (en) 2002-09-12
WO2002069947A3 true WO2002069947A3 (en) 2003-10-09

Family

ID=26948670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002002 WO2002069947A2 (en) 2001-01-12 2002-01-14 Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer

Country Status (6)

Country Link
JP (1) JP2004520421A (en)
KR (1) KR20040018328A (en)
CA (1) CA2434601A1 (en)
DE (1) DE10295684T9 (en)
GB (1) GB2389365A (en)
WO (1) WO2002069947A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
KR20040048411A (en) 2001-09-14 2004-06-09 메틸진, 인크. Inhibitors of histone deacetylase
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US7271195B2 (en) 2003-06-10 2007-09-18 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
EP1635800A2 (en) * 2003-06-10 2006-03-22 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
EP1663953A1 (en) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibitors of histone deacetylase
EP1574213B1 (en) * 2004-03-11 2008-07-09 Asan Laboratories Company (Cayman), Limited Use of histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US20080194681A1 (en) * 2004-12-09 2008-08-14 Kalypsys, Inc. Novel Inhibitors of Histone Deacetylase for the Treatment of Disease
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2452820T3 (en) 2006-04-07 2014-04-02 Methylgene, Inc. Benzamide derivatives as histone deacetylase inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
CA2668070A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035990A2 (en) * 1996-03-26 1997-10-02 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO2000023112A1 (en) * 1998-10-19 2000-04-27 Methylgene, Inc. Modulation of gene expression by combination therapy
WO2000071703A2 (en) * 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035990A2 (en) * 1996-03-26 1997-10-02 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO2000023112A1 (en) * 1998-10-19 2000-04-27 Methylgene, Inc. Modulation of gene expression by combination therapy
WO2000071703A2 (en) * 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL_PAT [online] EBI; 27 September 2001 (2001-09-27), METHYLGENE INC.: "Sequence 11 from Patent WO0170675", XP002232929, retrieved from WWW.EBI.AC.UK Database accession no. AX456081 *
DATABASE EMBL_PAT [online] EBI; 27 September 2001 (2001-09-27), METHYLGENE INC.: "Sequence 4 from Patent WO0170675", XP002232928, retrieved from WWW.EBI.AC.UK Database accession no. AX456074 *
GROZINGER CHRISTINA M ET AL: "Three proteins define a class of human histone deacetylases related to yeast Hda1p", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 9, 27 April 1999 (1999-04-27), pages 4868 - 4873, XP002159644, ISSN: 0027-8424 *
MANFRED JUNG ET AL: "Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 22, 4 November 1999 (1999-11-04), pages 4669 - 4679, XP002144226, ISSN: 0022-2623 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors

Also Published As

Publication number Publication date
JP2004520421A (en) 2004-07-08
CA2434601A1 (en) 2002-09-12
DE10295684T1 (en) 2003-11-20
GB0316313D0 (en) 2003-08-13
DE10295684T9 (en) 2004-10-14
GB2389365A (en) 2003-12-10
KR20040018328A (en) 2004-03-03
WO2002069947A2 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
WO2002069947A3 (en) Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
WO2003006652A3 (en) Inhibition of specific histone deacetylase isoforms
WO2004005513A3 (en) Methods for specifically inhibiting histone deacetylase-7 and 8
WO2001070675A3 (en) Inhibitors of histone deacetylase
MXPA04002397A (en) Inhibitors of histone deacetylase.
WO2006060382A3 (en) Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
ATE463490T1 (en) HISTONE DEACETYLASE INHIBITORS
EP1748046A3 (en) Inhibitors of histone deacetylase
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2000071703A3 (en) Inhibition of histone deacetylase
EP1476457A4 (en) RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SiNA)
HK1044528A1 (en) Monoamine reuptake inhibitors for treatment of cnsdisorders.
BRPI0411275A (en) carbonyl compounds as histone deacetylase inhibitors for treating diseases; pharmaceutical composition; method of modulating hdac catalytically activity; method of treating disease in an individual; use of a compound or composition; inhibit hdac method
WO2000023567A3 (en) Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
AU2003287254A8 (en) Inhibition of gene expression using rna interfering agents
WO2002050285A3 (en) Histone deacetylase-related gene and protein
WO2001057206A3 (en) Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
WO2001088124A3 (en) Method and reagent for the inhibition of erg
IL163875A0 (en) Methods, compositions, and kits for enhancing oli gonucleotide mediated nucleic acid sequence alteration using compositions comprising a histone de
WO2001007579A3 (en) Methods and compositions for determining enzymatic activity
GB0427814D0 (en) RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2002091926A3 (en) Inhibitors of dna methyltransferase isoforms
DE60333747D1 (en) DNA ENZYME FOR INHIBITING PLASMINOGENACTIVATOR INHIBITOR-1
WO2004046327A3 (en) Inhibitory oliogonucleotides targeted to bcl-2
WO2003014340A3 (en) Human histone deacetylase-related gene and protein hdac10

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

ENP Entry into the national phase

Ref document number: 0316313

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20020114

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002304328

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434601

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037009362

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200350045

Country of ref document: ES

Ref document number: P200350045

Country of ref document: ES

Ref document number: 2002569124

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PV2003-2177

Country of ref document: CZ

RET De translation (de og part 6b)

Ref document number: 10295684

Country of ref document: DE

Date of ref document: 20031120

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10295684

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 1020037009362

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2003-2177

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 200350045

Country of ref document: ES

Kind code of ref document: A